Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3717)	4/30/1998 9:57:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 7041

Did you not find it at that url. It was a very lengthy article with interesting comments about ZONA.

To: Linda Kaplan who wrote (3717)	5/1/1998 12:44:00 AM
From: LoLoLoLita	Read Replies (1) \| Respond to of 7041

Linda, Where did you learn that the 40% effectiveness figure came from the CEO, and that it was, nonetheless, a lie? Did you call the WSJ reporter and ask the source? And if it was the CEO, how do you know he was lying? This thread is so chock full of liar, liar, pants on fire messages that it's hard to separate the few grains of wheat from all the chaff. I asked Bradpalm where he got his data on the Phase III dropout rate, and got no tangible response. Maybe you can provide the source for your present claims that I'm replying to. But first, aren't your aware that most any test group is "prescreened"? PFE did it with Viagra, after all. They only accepted people who had had successful intercourse at least once in the past month, as I recall. I'm a scientist of sorts. Scientists want facts, based on data. Rumors don't count a whit for me. David